千亿制药巨头,最新公告!

每日经济新闻
Mar 04

3月4日早间,中国生物制药公告,附属正大天晴与跨国药企赛诺菲就JAK/ROCK抑制剂罗伐昔替尼订立全球独家授权协议,将获得1.35亿美元首付款及最高13.95亿美元里程碑款,并享有双位数阶梯式销售特许权使用费。  罗伐昔替尼是一款全球首创(First-in-Class)的新型、强效口服小分子JAK/ROCK抑制剂,通过双通路协同实现抗炎与抗纤维化。一方面靶向JAK/STAT通路阻断炎症信号传导,...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10